CA
TELO icon

Clearstead Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Clearstead Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Hold
12,530
– – ﹤0.01% 1853
2026
Q1 		$16.3K Hold
12,530
– – ﹤0.01% 1492
2025
Q4 		$16.7K Hold
12,530
– – ﹤0.01% 1764
2025
Q3 		$17.4K Buy
+12,530
New +$18.9K ﹤0.01% 1708

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Clearstead Advisors's TELO Position: Q2 2026 in Review

Clearstead Advisors held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 12,530 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1853.

Clearstead Advisors first reported a position in TELO in Q3 2025 and has held it in 4 quarters since. The position peaked at $17.4K in Q3 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Clearstead Advisors held 12,530 shares of Telomir Pharmaceuticals worth $16K as of Q2 2026.
  • Clearstead Advisors left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1853 holding.
  • Clearstead Advisors first reported a position in Telomir Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Telomir Pharmaceuticals position peaked at $17.4K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.